The Huaxia Sci-Tech Medical ETF (588130) has seen continuous net capital inflows for 7 consecutive days, ranking first among peers in average daily turnover over the past 7 days.

Data shows that as of July 28, the Huaxia Sci-Tech Medical ETF (588130) has achieved net capital inflows for 7 consecutive trading days, with sustained investor attention. The average daily turnover over the past 7 trading days exceeded 65 million yuan, ranking first among similar targets, indicating active trading and good liquidity.

Huaxin Securities believes that attention should be paid to the long-term value of innovative drugs, considering the realization of value from a longer perspective. Since 2024, the valuation expansion of the innovative drug sector has relied on the restructuring of the value of innovative drugs through their global expansion, especially the landing of major Business Development (BD) deals, which have provided new value anchors for the overseas market value of innovative drugs. The total transaction amount of short-term licensing deals provides a benchmark for assessing the realization of long-term value.

The Huaxia Sci-Tech Medical ETF (588130) provides a convenient tool for low-threshold one-click layout of the sci-tech medical sector, tracking the SSE Science and Technology Innovation Board Biomedical Index. The 20% price limit on the Science and Technology Innovation Board offers high elasticity. This index is highly concentrated in three core tracks: chemical pharmaceuticals, medical devices, and biological products, with a combined weight exceeding 91%, helping ordinary investors seize the long-term development opportunities in the innovative drug and device sectors. (Off-exchange feeder A: 027142; Feeder C: 027143).